EP Patent

EP4029859A1 — 2-oxothiazolidin-4-one derivatives active as transthyretin ligands and uses thereof

Assigned to Bsim Therapeutics S A · Expires 2022-07-20 · 4y expired

What this patent protects

Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for ex…

USPTO Abstract

Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).

Drugs covered by this patent

Patent Metadata

Patent number
EP4029859A1
Jurisdiction
EP
Classification
—
Expires
2022-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Bsim Therapeutics S A
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.